Pharmaceutical - AstraZeneca, Gastro-intestinals

Filter

Popular Filters

FDA approves AstraZeneca’s Movantik for opioid-induced constipation

FDA approves AstraZeneca’s Movantik for opioid-induced constipation

17-09-2014

The US Food and Drug Administration yesterday approved Movantik (naloxegol), an oral treatment for opioid-induced…

AstraZenecaGastro-intestinalsMovantikNektar TherapeuticsPharmaceuticalRegulationUSA

AstraZeneca reports positive results from lesinurad trial for gout

AstraZeneca reports positive results from lesinurad trial for gout

13-08-2014

Anglo-Swedish drug major AstraZeneca has said its Phase III trials of lesinurad in combination with xanthine…

AstraZenecaEuropeGastro-intestinalslesinuradPharmaceuticalResearchSymptomatic gout

Positive US FDA advisory panel view on PAMORAs

Positive US FDA advisory panel view on PAMORAs

13-06-2014

The majority of US Food and Drug Administration Anesthetic and Analgesic Drug Products Advisory Committee…

AstraZenecaGastro-intestinalsMovantiknaloxegolPharmaceuticalRegulationUSA

Hanmi launches esomeprazole product in USA despite AstraZeneca litigation

Hanmi launches esomeprazole product in USA despite AstraZeneca litigation

18-12-2013

South Korea-based Hanmi Pharmaceutical has announced that Esomezol (esomeprazole strontium) for the treatment…

Amneal PharmaAstraZenecaEsomeprazole MagnesiumEsomeprazole SodiumGastro-intestinalsGenericsHanmi PharmaceuticalLegalNexiumPharmaceuticalUSA

US FDA accepts AstraZeneca’s NDA for naloxegol

US FDA accepts AstraZeneca’s NDA for naloxegol

19-11-2013

The US Food and Drug Administration has accepted the New Drug Application for naloxegol, an investigational…

AstraZenecaGastro-intestinalsnaloxegolNektar TherapeuticsNorth AmericaPharmaceuticalRegulation

AstraZeneca reveals new safety data for naloxegol in OIC

AstraZeneca reveals new safety data for naloxegol in OIC

15-10-2013

AstraZeneca has released results of a Phase III long-term safety and tolerability study of the once-daily…

AstraZenecaGastro-intestinalsnaloxegolNeurologicalPharmaceuticalResearch

Opioid-induced constipation market expected to see rapid growth by 2017

Opioid-induced constipation market expected to see rapid growth by 2017

13-10-2013

The global market for opioid-induced constipation will increase significantly from $144.42 million in…

AstraZenecabevenopranCubist PharmaceuticalsEuropeGastro-intestinalsMarkets & MarketingnaloxegolNorth AmericaPharmaceuticalRelistorSalix Pharmaceuticals

US Appeals Court lifts temporary injunction on Hanmi Nexium generic NDA

03-10-2013

AstraZeneca said that the US Court of Appeals for the Federal Circuit (CAFC) lifted a temporary injunction…

AstraZenecaEsomeprazole MagnesiumGastro-intestinalsHanmi PharmaceuticalLegalNexiumNorth AmericaPharmaceuticalRegulation

AstraZeneca’s naloxegol marketing application accepted by EMA

AstraZeneca’s naloxegol marketing application accepted by EMA

27-09-2013

The European Medicines Agency has accepted AstraZeneca’s Marketing Authorization Application for naloxegol…

AstraZenecaEuropeGastro-intestinalsMarkets & MarketingnaloxegolNektar TherapeuticsPharmaceuticalRegulation

Nektar hedges bets on deal with AstraZeneca

12-08-2013

Along with presenting second-quarter financial results, Howard Robin, president and chief executive of…

AstraZenecaFinancialGastro-intestinalsLicensingnaloxegolNektar TherapeuticsPharmaceutical

AstraZeneca settles with Hanmi and Amneal over Nexium; Prepares for olaparib regulatory filing

03-06-2013

Anglo-Swedish drug major AstraZeneca (LSE: AZN) today (May 3) said it has entered into an agreement with…

Amneal PharmaAstraZenecaGastro-intestinalsGenericsHanmi PharmaceuticalLegalNexiumNorth AmericaolaparibOncologyPatentsPharmaceuticalRegulationResearch

AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA

22-05-2013

Anglo-Swedish drug major AstraZeneca (LSE: AZN) yesterday (May 21) presented the results of two pivotal…

Anti-viralsAstraZenecaBiotechnologyEuropeGastro-intestinalsGilead SciencesnaloxegolNektar TherapeuticsPharmaceuticalRegulationResearchsofosbuvir

Encouraging results for AstraZeneca's naloxegol in OIC

26-02-2013

Anglo-Swedish drug major AstraZeneca (LSE: AZN) has announced high-level results from KODIAC-08, an open-label,…

AstraZenecaGastro-intestinalsnaloxegolNeurologicalPharmaceuticalResearch

EU Court of Justice dismisses AstraZeneca appeal on patent settlement

07-12-2012

The European Union's highest court, the Court of Justice, yesterday dismissed the appeal of Anglo-Swedish…

AstraZenecaEuropeGastro-intestinalsLegalLosecPatentsPharmaceutical

AstraZeneca gains rights to sell Ironwood's IBS drug in China

24-10-2012

Anglo-Swedish drug major AstraZeneca (LSE: AZN) has entered into an agreement with the USA's Ironwood…

Asia-PacificAstraZenecaGastro-intestinalsIronwood PharmaceuticalsLicensinglinaclotideMarkets & MarketingNexiumNorth AmericaPharmaceutical

Pharmaceutical majors unite in Japan to combat H. pylori

18-09-2012

On August 31, nine pharmaceutical companies operating in Japan (Kyowa Hakko Kirin, Takeda Pharmaceutical,…

Antibiotics and Infectious diseasesAsia-PacificAstraZenecaGastro-intestinalsPharmaceuticalRegulationTakeda Pharmaceuticals

AstraZeneca to get $250 million-plus from OTC Nexium deal with Pfizer

15-08-2012

Anglo-Swedish drug major AstraZeneca (LSE: AZN) says it has entered into an agreement with Pfizer (NYSE:…

AstraZenecaFinancialGastro-intestinalsGlobalLicensingNexiumPfizerPharmaceutical

Merck & Co to continue posting sales and profits under AstraZeneca partnership

28-06-2012

US drug giant Merck & Co (NYSE: MRK) and Anglo-Swedish major AstraZeneca have amended the option agreement…

AstraZenecaFinancialGastro-intestinalsLicensingMerck & CoNexiumPharmaceuticalPrilosec

Back to top